Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Showing posts with label brain fat. Show all posts
Showing posts with label brain fat. Show all posts

Saturday, July 26, 2025

Disproving Dogma: How the Brain Uses Fat as Fuel

 How can your competent? doctor use this to power your brain during a stroke and save neurons?

Disproving Dogma: How the Brain Uses Fat as Fuel


Timothy Ryan, PhD, runs a lab at Weill Cornell Medicine in New York City, where the team focuses on studying synapses and adenosine triphosphate (ATP). Like most teams, they kick around lots of what-ifs. One day, a postdoctoral researcher, Mukesh Kumar, PhD, asked Ryan if fat could serve as a fuel to run a synapse.

Other parts of the body break down fat to make ATP, so why doesn’t the brain? After all, the brain is nearly 60% fat.

“My immediate reaction, honestly, was just that I had a bias because every review article says it doesn’t look like it does that,” Ryan said.Well, guess what.In their new studyNature Metabolism, Ryan and his team showed that a triglyceride-filled lipid droplet in the synapse of a mouse is broken down by neurons into fatty acids, which are sent to mitochondria to produce ATP. The process is similar to how muscle in other parts of the body uses fat to make ATP. It’s a somewhat hidden process because it does not occur when at rest (lipid droplets are present before exercise but not afterward). Like most discoveries, it began with the question. But the path to the discovery meant delving into decades of dogma. Ryan initially told Kumar it’s going to be a pretty high bar to prove the brain uses fat as fuel. “But then I started reading the background literature of where it came from,” said Ryan. “And it really started in 1933.” Nearly 100 Years of Dogma On the Line Back then, the foundational research demonstrated respiration in muscle tissue when given fat for fuel, but the same wasn’t apparent when the researchers tried brain tissue.“The problem is that when you chop up brain, you make a really nonfunctional tissue. The cells can’t do anything anymore. I’m not blaming them. In 1933, we didn’t have that level of sophistication,” Ryan said. But decades of subsequent laboratory approaches also used brain tissue and increasingly sophisticated techniques — looking for fat-fueled brain tissue to produce radioactive CO2 or examining processes at the cellular level. Another reason it seemed unlikely that the brain metabolizes fat is because electron microscopy of brain cells has never shown lipid droplets. Combined with metabolism experiments, the case seemed settled — other parts of the body metabolize fat but the brain didn’t seem to do it in lab experiments, and lipid droplets didn’t appear on high resolution images. Neurologist John K. Fink, MD, said he wasn’t shocked by Ryan’s findings “because I don’t tightly hold to the dogma that neurons cannot utilize triglycerides as a source of energy. Are other people shocked? Only to the degree that they hold tightly to dogma.” “This exposes not so much new areas of neurology but how cautious we have to be about overzealous acceptance,” said Fink, a professor at the University of Michigan Medical School, Ann Arbor, Michigan, who also practices in the area of spastic paraplegia. These latest findings, Fink said, offer an important basis for further exploring brain function in low-glucose conditions. “Now that we know that it can happen, we need to know to what extent does it happen,” he said. What Does It Mean to Not See Something? The question of does the brain use fat persisted in Ryan’s lab, which is well-known for its 2014 work demonstrating that synapses don’t store ATP and it’s produced on demand. The on-demand nature is important — when ATP can’t be made on demand, things start to go wrong. “Keeping synapses working is the most important thing in the brain. I say that as a person who studies synapses for a living, but I don’t think anyone would argue that that’s the business end of the brain. It’s synaptic communication,” said Ryan. “That was our motivation — to learn all the rules we can about what controls how well we do this job.” A primary question that needed to be answered in that exploration was: What fuel is used to make ATP? Glucose is the standard, Ryan acknowledged, but “the brain doesn’t tolerate not having enough fuel because it needs to use it all the time. And so that brought up the question: What other things might you use?” Ketones were something they considered, partly driven by the fact that a severe ketogenic diet is sometimes effective as a last recourse for treating children with epilepsy. The link between ketones and the brain is unclear. “Ketones are made probably in the liver and get shipped to the brain, and neurons use the ketones. So we have studied this, but we don’t quite understand why that ends up resetting things well,” Ryan said. Another fuel the brain may use is fat, the team hypothesized. Muscle also needs on-demand fuel and uses glucose. “But muscle famously is also well-known to use fat,” Ryan said, noting that it’s a very now-you-see-it, now-you-don’t process. “Actually, if you look at resting muscle in a biopsy, you discover that resting muscle has lipid droplets,” he said. “So if you look at fat cells, which we all have — and we all have more and more of as we age — those cells are full of big lipid droplets. They’re giant. That’s how fat is stored, in lipid droplets.” The lipid droplets are perfect spheres. But after exercise, most lipid droplets are gone because they were used as fuel to make ATP. “So what does it mean to not see lipid droplets in the brain? It could well mean that part of the brain is resting,” Ryan said. Ryan and the team also leveraged understanding of genetic susceptibilities for diseases like Parkinson’s disease and spastic paraplegia using existing research about how mutations affect enzymes involved in lipid metabolism. A DDHD2 mutation — which is linked to hereditary spastic paraplegia type 54 — can drive a huge buildup of lipid droplets in the brain, as shown in previous work by Benjamin Cravatt, PhD, of Scripps Research in La Jolla, California. “We knew that the neurons were accumulating lipid droplets, but that’s where we left it,” said Cravatt, a chemical biologist. The implication, Ryan said, is that if the brain doesn’t have the enzyme made by DDHD2, it can’t take apart lipid droplets to make fatty acids, which can’t then be given to mitochondria to make ATP. “Luckily for us, Cravatt also made — he’s a chemist — a small molecule inhibitor, so we didn’t just have to rely on knockout mice. We could do really fast experiments, where we could block this enzyme with a drug that he made…in 10 hours, you could see a huge buildup of lipid droplets in the neurons.” Turns out the inhibitor Cravatt made was reversible. “That allowed us to pull all the tricks my lab is good at and to show that now you could run a synapse with absolutely no glucose whatsoever,” Ryan said. “If you would build up lipid droplets, you could skate by as if nothing was wrong without any fuel — like if you did that, you would be insulin resistant because it wouldn’t matter if your glucose drops because for a little while, you could run a synapse without any fuel whatsoever because it had its fuel depot.” It’s a possibility, Ryan said, that as we age, we become more reliant on this backup fuel source for the brain, posing potential areas of future research that intersect with dementia and other neurologic diseases. “What we’re seeing in the DDHD2-disrupted humans that get spasmodic hyperplasia is obviously an extreme nonphysiologic outcome of losing the enzyme,” Cravatt said. “But what does the enzyme normally do? And is it normally relevant? Is a triglyceride hydrolase activity relevant for brain energetics, brain signaling? This paper really speaks to that quite well — there appears to be an intriguing role for lipid metabolism as a source of energy and fuel in neurons normally as part of their signaling.”

Friday, August 28, 2015

Alzheimer’s disease thought to be accelerated by an abnormal build-up of fat in the brain

What is your doctor doing with this discovery?
What is your doctor doing to prevent your 33% dementia chance post-stroke from an Australian study? ANYTHING AT ALL? Or is your doctor expecting you to figure this out on your own? 

Alzheimer’s disease thought to be accelerated by an abnormal build-up of fat in the brain



People with Alzheimer’s disease have fat deposits in the brain. For the first time since the disease was described 109 years ago, researchers affiliated with the University of Montreal Hospital Research Centre (CRCHUM) have discovered accumulations of fat droplets in the brain of patients who died from the disease and have identified the nature of the fat.
This breakthrough, published today in the journal Cell Stem Cell, opens up a new avenue in the search for a medication to cure or slow the progression of Alzheimer’s disease. "We found fatty acid deposits in the brain of patients who died from the disease and in mice that were genetically modified to develop Alzheimer’s disease. Our experiments suggest that these abnormal fat deposits could be a trigger for the disease", said Karl Fernandes, a researcher at the CRCHUM and a professor at University of Montreal.
Over 47.5 million people worldwide have Alzheimer’s disease or some other type of dementia, according to the World Health Organization. Despite decades of research, the only medications currently available treat the symptoms alone.
This study highlights what might prove to be a missing link in the field. Researchers initially tried to understand why the brain’s stem cells, which normally help repair brain damage, are unresponsive in Alzheimer’s disease. Doctoral student Laura Hamilton was astonished to find fat droplets near the stem cells, on the inner surface of the brain in mice predisposed to develop the disease. "We realized that Dr. Alois Alzheimer himself had noted the presence of lipid accumulations in patients’ brains after their death when he first described the disease in 1906. But this observation was dismissed and largely forgotten due to the complexity of lipid biochemistry", said Laura Hamilton.
The researchers examined the brains of nine patients who died from Alzheimer’s disease and found significantly more fat droplets compared with five healthy brains. A team of chemists from University of Montreal led by Pierre Chaurand then used an advanced mass spectrometry technique to identify these fat deposits as triglycerides enriched with specific fatty acids, which can also be found in animal fats and vegetable oils.
"We discovered that these fatty acids are produced by the brain, that they build up slowly with normal aging, but that the process is accelerated significantly in the presence of genes that predispose to Alzheimer’s disease", explained Karl Fernandes. In mice predisposed to the disease, we showed that these fatty acids accumulate very early on, at two months of age, which corresponds to the early twenties in humans. Therefore, we think that the build-up of fatty acids is not a consequence but rather a cause or accelerator of the disease."
Fortunately, there are pharmacological inhibitors of the enzyme that produces these fatty acids. These molecules, which are currently being tested for metabolic diseases such as obesity, could be effective in treating Alzheimer’s disease. "We succeeded in preventing these fatty acids from building up in the brains of mice predisposed to the disease. The impact of this treatment on all the aspects of the disease is not yet known, but it significantly increased stem cell activity," explained Karl Fernandes. "This is very promising because stem cells play an important role in learning, memory and regeneration."
This discovery lends support to the argument that Alzheimer’s disease is a metabolic brain disease, rather like obesity or diabetes are peripheral metabolic diseases. Karl Fernandes’ team is continuing its experiments to verify whether this new approach can prevent or delay the problems with memory, learning and depression associated with the disease.